Hepatitis A

Yes. Hepatitis A is a self-limiting infection, the immune system clears the virus on its own without antiviral medication. Supportive care (rest, adequate fluids, nutritious eating, no alcohol) is all that is needed for most people. The vast majority recover fully within a few weeks to two months, after which they are immune for life. A minority (roughly 10–15%) experience a relapsing course stretching 6–9 months, but even this eventually resolves completely. Unlike hepatitis B and C, hepatitis A never becomes chronic.

Yes and no, it depends on how you define the term. Hepatitis A can be transmitted sexually, primarily through oral-anal contact (rimming) and close sexual contact with an infected person. CDC-documented outbreaks among MSM confirm sexual transmission is a real and significant route, which is why MSM are a priority vaccination group. However, hepatitis A also spreads readily through contaminated food and water, close household contact, and shared drug equipment, routes with no sexual component. It is more accurate to say HAV is an infection that can be sexually transmitted than a purely sexually transmitted infection. Vaccination is the only reliable protection regardless of exposure route.

After exposure, HAV incubates for 15–50 days (average ~28 days) before symptoms appear. Dark, tea-colored urine is often the very first noticeable change. Systemic symptoms, fatigue, nausea, vomiting, loss of appetite, low-grade fever, and upper right abdominal pain, typically follow within days. Jaundice (yellowing of skin and eyes) appears a few days after systemic symptoms and can be alarming in appearance but generally signals active immune response. Acute illness usually lasts 1–2 months. In roughly 10–15% of cases, symptoms resolve and then return (relapsing hepatitis A), potentially extending illness over 6–9 months. Full recovery and lifelong immunity follow in virtually all cases.

Most people with hepatitis A are ill for 2–8 weeks and then recover fully. Mild cases may resolve in under two weeks; severe cases, particularly in older adults or those with pre-existing liver disease, can last longer and may require hospitalization. About 10–15% of people experience a relapsing course where symptoms return after apparent recovery, stretching total illness over 6–9 months. Even prolonged or relapsing hepatitis A always resolves completely without becoming chronic, which distinguishes it from hepatitis B and C.

No. Once you recover from hepatitis A, or complete the full two-dose vaccine series, you are immune for life. The immune system produces IgG anti-HAV antibodies that persist indefinitely in the bloodstream and provide complete protection against reinfection. This lifelong immunity is one of the most important distinctions between hepatitis A and hepatitis B or C, which can establish chronic infections. A total/IgG anti-HAV blood test can confirm your immune status at any time if needed for travel, occupational clearance, or peace of mind.

Hepatitis A spreads sexually primarily through oral-anal contact (rimming), placing the mouth on or near the anus of someone who is shedding the virus in their stool. This route can transmit a sufficient inoculum of HAV to establish infection. Outbreaks among MSM are well-documented and are a primary reason MSM are a CDC priority vaccination group. Anal intercourse and close sexual contact may also transmit HAV, though oral-anal contact is the most efficient sexual route. Condoms offer limited protection because they do not cover the anal area during rimming; vaccination is the only reliably protective prevention strategy for people who engage in oral-anal sex.

Yes: the hepatitis A vaccine is one of the most effective vaccines available, achieving 95–100% seroprotection. Two doses of Havrix or Vaqta (given 6 months apart) provide long-lasting, likely lifelong protection. A combined hepatitis A + B vaccine (Twinrix) is available for adults 18+ and requires three doses over 6 months. People who should be vaccinated include: all children at 12–23 months; unvaccinated people through age 18; MSM; people who use drugs; people experiencing homelessness; travelers to high-prevalence countries; people with chronic liver disease or HIV; food-service workers and healthcare workers; and any unvaccinated adult who wants protection.

Three key differences set hepatitis A apart. Transmission: HAV spreads mainly fecal-oral (contaminated food, water, close contact, oral-anal sex); HBV and HCV spread primarily through blood and body fluids (sex, shared needles, childbirth). Chronicity: HAV never becomes chronic, everyone clears it and gains lifelong immunity. HBV can become chronic in ~5% of adults and ~90% of newborns; HCV becomes chronic in ~50–55% of cases and can silently damage the liver for decades. Vaccine: Safe, highly effective vaccines exist for both hepatitis A and hepatitis B. There is currently no approved vaccine for hepatitis C.

Act quickly, time is critical. Post-exposure prophylaxis (PEP) given within 2 weeks of exposure can prevent illness or significantly reduce its severity. For healthy people aged 12 months, 40 years: the hepatitis A vaccine is preferred and is highly effective. For immunocompromised individuals, those with chronic liver disease, adults over 40, infants under 12 months, or anyone with vaccine contraindications: immune globulin (IG 0.1 mL/kg IM) is preferred, and can be given alongside the vaccine for people who fall into more than one category. Contact your health department, urgent-care clinic, or primary-care provider as soon as you learn of a potential exposure. All household members, sexual partners, and people who shared drugs or drug equipment with the case should also be evaluated.

Yes, significantly. Hepatitis A causes much more severe illness in people with pre-existing liver disease, including chronic hepatitis B or C, cirrhosis, alcoholic liver disease, and nonalcoholic fatty liver disease (NAFLD). Fulminant (acute) liver failure, a rare but life-threatening complication, is substantially more common in this group and may require emergency liver transplantation. If you have chronic liver disease and have not previously been vaccinated or infected with HAV, hepatitis A vaccination is strongly and urgently recommended regardless of exposure status.

Children under 6 infected with HAV typically have no recognizable illness, no jaundice, no nausea, no fatigue, because the immune inflammatory response that causes most hepatitis A symptoms is less pronounced in young children. Despite being asymptomatic, they shed large quantities of HAV in their stool for weeks before and after the expected symptom window. This makes unrecognized infection in young children a powerful driver of household and daycare outbreaks, adults caring for these children can become significantly ill from an exposure they never knew had occurred. Vaccination at 12–23 months closes this gap.